TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: number of subjects with adrenal suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gym visits per week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gestational week at delivery
Endpoint domain: Physiological/clinical
Primary endpoint: plasma HIV-1 RNA BLQ (< 50 copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: World Health Organization-Quality of Life (WHO-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depression Anxiety and Stress Scale (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brief Pain Inventory (BPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: World Health Organization Disability Assessment Schedule II (WHODAS-II)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of Serum triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective Response Rate (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and toxicity (maximum tolerated dose (MTD))
Endpoint domain: Adverse events/effects
Primary endpoint: Delta SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ln-transformed Cmax,ss of baseline-adjusted total EPA, total DHA, and total EPA+DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ln-transformed AUC0-tau of baseline-adjusted total EPA, total DHA, and total EPA+DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Global Impression - Improvement/Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Performance of the Microneedle Adapter in the inner forearm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the Microneedle Adapter in the deltoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the Microneedle Adapter in the thigh
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mismatch ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Occult Myocardial Scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of solicited and unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of symptomatic cases of virologically confirmed COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: process skills scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance scores in daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sense of competence scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients cooled to 32-34°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Glutamine and Myoinositol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Connectivity Assessed by Resting-state fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional Anisotropy Assessed Using DTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in PSG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with significant pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in FTL status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FTL symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of traditional cardiovascular risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New diffusion-weighted lesions on cerebral MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to obtain discharge criteria from recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No host inflammatory reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thigh muscle protein fractional synthetic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in numerical ratings on pain diaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily pain numerical ratings at rest and with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total opiate dose via patient controlled IV hydromorphone
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in Urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in Bladder pain/discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ocular itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological fusion gleno humeral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow of CSF for any blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total wound diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of intravenous infusion of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra and inter-subjects variability of pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edema - Cheek Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trismus - Vertical Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain - (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daytime incontinence-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Relative number of wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical manifestations of PCOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical manifestations of PCOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of biomarkers for invasive pulmonary aspergillosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time for placement of supraglottic device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patient responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Back pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor power evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in circulating Interleukin-6 levels over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Vasopressor requirements over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative intensive care mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: change in muscle tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in basic motor abilities of the upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes From Baseline in Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes From Baseline in Non-Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Skills Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Theory of Mind Battery and Inventory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Structured Play Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MRI changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leukocyte functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: (anti-)oxidant status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic floor muscle strength (PFMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Stress urinary incontinence (SUI) severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Soft-tissue attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural and functional characteristics of neurons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of T. solium cysticercosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of taeniosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anti-hepatitis A virus (HAV) antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Thermic Effect of Meals (TEM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants That Completed Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resuscitated arrest or death during sports
Endpoint domain: Mortality/survival
Primary endpoint: Injury during sports due to arrhythmic symptoms and/or shock
Endpoint domain: Adverse events/effects
Primary endpoint: ACR 20% improvement response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clock Gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10% decrement of creatinine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in 6-minutes walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk factors for osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in motor evoked potential size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resolution time of the lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Health Questionnaire-9 Items (PHQ-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: # of sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction with the treatment program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ctDNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columbia-Suicide Severity Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: quick DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serious Adverse Events (SAEs) and Serious Adverse Reactions (SARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Rate of Secondary Surgical Interventions Due to the Optical Properties of the Lens
Endpoint domain: Adverse events/effects
Primary endpoint: Photopic Uncorrected Distance Visual Acuity (UDVA) for First Implanted Eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major complication rate of subclavian catheterization
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue factor positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric change in facial tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decline in oxygen saturation to ≤ 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CO2 increase of 15% or more above baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: deviation in pupillary measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dystonia phenomenology improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c (glycated hemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Blood Oxygen Level Dependent (BOLD) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete cure of the target nail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Change in epidermal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in collagen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of the impact of therapy on daily life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of disease
Endpoint domain: Mortality/survival
Primary endpoint: Age at diagnosis of disease
Endpoint domain: Mortality/survival
Primary endpoint: Risk of death or disease in relative
Endpoint domain: Mortality/survival
Primary endpoint: Biotin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of bleeding sources
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survivin positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self-reported music use and perceived benefits of music questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-patient bioavailability of clofarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics of clofarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability measured by Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of paracetamol absorption measured by Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of Cirrhosis Based on Hepatic Impairment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence rate of T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of permanent atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adipose tissue inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Appearance of senescent cells around wound sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: New or progressive multiple organ dysfunction syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bidirectional conduction block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients With Grade 3 Adverse Events That Effect Vital Organ Function or Any Grade 4 or Higher Non-hematologic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: 2-year Progression-free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with a negative RT-PCR test result to COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vision Satisfaction in Bright Lighting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in hand grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Kansas City Cardiomyopathy Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of breast cancer incidence attributable to mutations in such genes
Endpoint domain: Mortality/survival
Primary endpoint: Change in Percent Collagen I Deposition on Lymph Node Pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Percent Collagen I Deposition on Subcutaneous Abdominal Adipose Tissue Pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number of participants with successful bone healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to heal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants With a Major Pathological Response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone formation after sinus augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: average post operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Achieved PASI 75 at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients Who Achieved sPGA 0/1 at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of sexual partners for vaginal intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of incidents of vaginal sex without using hormonal contraception, copper IUD, or condoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of incidents of vaginal sex without condoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cancer-Related Fatigue Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cancer-Related Fatigue Fatigability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutation rate of IL-10RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in modified Rankin Scale (mRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in National Institutes of Health Stroke Scale (NIHSS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Barthel Index (BI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients taking alternative medicines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Apnea-Hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Engraftment assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in incretines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Chronic Obstructive Pulmonary Disease Dyspnea Questionnaire (CCQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of MSI in circulating tumor DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Confirm Lung Isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Density of the gland measured by electronic palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds ratios of risk factors for venous ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global Rating of Change (GROC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status